Alert for Melbourne's Chadstone Shopping Centre as two more locally acquired cases of measles are confirmed
Melbourne's largest shopping centre has been rocked by measles after Victoria recorded two more locally acquired cases of the highly contagious disease.
The new cases visited Chadstone Shopping Centre, hospitals, universities and a number of smaller shopping centres in greater Melbourne while potentially infectious, according to an alert issued by Victoria's Department of Health on Friday.
It is believed one of the infected people may have been working at beauty store MECCA, with shoppers who visited the Chadstone MECCA on Thursday and Friday last week asked to monitor for symptoms.
The Chadstone Kmart and lower level food court have also been listed as exposure sites, bringing the total number of exposure sites across greater Melbourne close to 30.
The list includes Dandenong Hospital, Frankston Hospital, Monash University's Caulfield and Peninsula campuses, metro trains, Wellington Village Shopping Centre, The Glen Shopping Centre and Stud Park Shopping Centre.
Both of the new infections are linked to another recently confirmed case, and the department is warning that there is now an increased risk of measles in greater Melbourne.
'A significant number of recent measles cases have acquired their infection locally in Victoria,' the alert said.
'There is also an ongoing risk of measles being imported into Victoria by travellers returning from overseas or interstate.'
Measles, which can be avoided with a vaccine, is a contagious viral illness that causes rash and fever. In some cases, it can also cause serious health complications, including pneumonia and encephalitis.
The disease is spread through the air when someone who is infectious coughs or sneezes, and a person with measles is infectious from about 24 before the onset of symptoms until four days after the rash appears.
Symptoms can develop between seven to 18 days after exposure and include fever, cough, sore or red eyes, runny nose, and feeling generally unwell, followed by a red maculopapular rash.
The rash usually starts on the face before spreading down the body.
Young infants and pregnant women are particularly vulnerable to suffering serious complications if they contract the virus.
The local cases are taking place as global case numbers are also rising, potentially exposing Australian travellers to the virus, the department said.
'There are currently outbreaks reported in multiple countries and regions, including Pakistan, Indonesia, Vietnam, Thailand, India, Africa, Europe and the UK, the Middle East, and North America,' the alert stated.
A full exposure site list has been posted to the health department's website.
'Vaccination is the best way to protect yourself and others,' the department stated.
'Anyone who has attended a listed exposure site during the specified date and time or spent time in greater Melbourne from late April should monitor for symptoms and seek medical care if symptoms develop for up to 18 days after the exposure.
'Anyone who attended a listed exposure site and is not fully vaccinated for measles may be eligible to receive the MMR vaccine if they present within 72 hours of exposure.
'Anyone who is immunocompromised or pregnant and not fully vaccinated for measles should seek medical review if within six days of exposure to a measles case.
'Anyone who develops symptoms of measles should seek medical care and testing for measles.
'Call the health service beforehand to advise that you may have been exposed to measles and wear a face mask.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
an hour ago
- ABC News
What you need to know about dietary fibre and digestion
People share a lot of their lives on social media. This can even include digestion details, with content about "staying regular", bloating and fibre far from off limits on platforms such as Instagram and TikTok. Food and nutrition scientist Emma Beckett, based in Newcastle/Awabakal, says she is glad these conversations are bringing fibre into focus. "I feel like lately everything's about protein and prioritising protein, and we've kind of forgotten about everything else, including fibre," she says. "Talking about digestive health — particularly pooping — was very taboo for a long time." Dr Beckett says fibre falls into two major categories, soluble fibre and insoluble fibre. She says soluble fibre "forms a gel-like substance when it's mixed with water". This gel-like consistency "helps us to feel fuller for longer" and some soluble fibres can also be classified as prebiotics, which help feed beneficial gut bacteria. According to Australia's public health website Healthdirect, soluble fibre is found in oats and barley, fruit and vegetables. It's also found in legumes such as chickpeas, lentils and beans. You may have heard insoluble fibre described as roughage. "I remember at school being told that fibre is like the gut's toothbrush," Dr Beckett says. Insoluble fibre is found in high-fibre and wholegrain breads and cereals, the outer skins of fruits and vegetables and nuts and seeds. The Australian dietary guidelines recommend 30 grams of fibre a day for adult men and 25 grams for women. Dr Beckett says while fibre falls into two main categories (and even more subcategories), dietary recommendations are based on general fibre intake. Considering daily recommendations and how often we eat, she says meals with 10 grams of fibre or more are a "fibre superstar", and 6 to 10 grams is a "good source". However, Dr Beckett says prioritising ingredients with fibre is more practical than "obsessing over the grams". "If you're having vegetables in your lunch and your dinner, if you're eating as many legumes as possible, if you're eating as many whole grains as possible, then you don't even need to worry about the number." Vincent Ho is a gastroenterologist and associate professor of medicine at Western Sydney University, and says patients are often confused about which foods are high in fibre. Dr Ho says a supplement is not enough to get your recommended daily intake, with a tablespoon of psyllium husk only containing about 2 grams of fibre. Megan Rebuli is a research dietician in health and biosecurity at the CSIRO in Adelaide, on the traditional country of the Kaurna people. If you're looking to get more fibre at mealtimes you can make some simple swaps, she says. "For example, swapping white bread for wholegrain bread [or] swapping white pasta for wholegrain pasta." You can also add legumes to salads and curries, she says. Dr Beckett says "generally speaking, Australians don't eat enough legumes" and they're a "stand-out" when it comes to high-fibre foods. Dr Beckett says these recipes contain more than 10 grams of protein per serve. Dr Beckett says "one of the immediate consequences of not having enough fibre in your diet is constipation." This could lead to extreme discomfort and even haemorrhoids from straining, she says. What's considered normal frequency for a bowel movement varies person to person and "it could be anywhere from three times a day to three times a week". Dr Ho says constipation can also lead to anal fissures (small tears around the area) "exacerbated by constipation and straining". He says eating fibre can help reduce cholesterol and blood sugar levels, and also reduces the risk of colorectal cancer (also known as bowel cancer). If you're not getting enough, "your cholesterol levels and your blood sugar levels can be elevated", as well as your cancer risk. Ms Rebuli says being physically active and consuming dietary fibre has been shown to decrease your risk, but there are a range of lifestyle and genetic factors that may also play a part. This article contains general information only. You should consider obtaining independent professional advice in relation to your particular circumstances.
ABC News
2 hours ago
- ABC News
ABC announces the TOP 5 recipients for 2025
The ABC has revealed this year's inspiring researchers to take part in the ABC TOP 5 media residencies. The five successful applicants from each of the three fields – Science, Humanities & the Arts, will be in residence at the ABC offices for two-weeks of media training and practical experience. They will be working alongside some of Australia's best journalists and broadcasters, to get a better understanding of how best to communicate their vital research with the world. 'Academia and news reporting are facing extraordinary challenges around the world', says ABC Chair Kim Williams. 'So, the ABC is proud to be partnering with four leading educational and cultural institutions, ensuring that important ideas and new research is discussed and disseminated to broader audiences - ensuring that the ABC delivers information that Australians can rely upon and trust'. Dina Rosendorff is the Manager of ABC Radio National. 'The TOP 5 is a unique Radio National program that teams up early career researchers with some of the ABC's best storytellers. It's a chance for audiences to hear bold new ideas from rising stars in Australian research - and for those researchers to sharpen their skills in bringing their work to life for the public.' THE 2025 ABC TOP 5 ARE: SCIENCE Dr Chantelle Blachut : Postdoctoral Fellow – UNSW, ADFA ACT. Uses mathematics to investigate unexpected behaviour in natural structures like bushfires on mountain-tops or blobs of cold air over Antarctica. : Postdoctoral Fellow – UNSW, ADFA ACT. Uses mathematics to investigate unexpected behaviour in natural structures like bushfires on mountain-tops or blobs of cold air over Antarctica. Dr Amal Osman : Postdoctoral Research Fellow, FHMRI Sleep Health - Flinders University. Specialised physiology techniques to develop new, tailored treatment for obstructive sleep apnoea. : Postdoctoral Research Fellow, FHMRI Sleep Health - Flinders University. Specialised physiology techniques to develop new, tailored treatment for obstructive sleep apnoea. Dr Howe Zhu : Lecturer in Interaction Design – USYD. Explores the intersection of Human-Computer Interaction and Cognitive Neuroscience, leveraging insights from cognitive computing and extended reality to design human-centred technologies that support perception, attention, and immersive interaction. : Lecturer in Interaction Design – USYD. Explores the intersection of Human-Computer Interaction and Cognitive Neuroscience, leveraging insights from cognitive computing and extended reality to design human-centred technologies that support perception, attention, and immersive interaction. Dr Chantelle Doyle : Research Associate – UNSW. Pairing new methods, like genomics, with classic techniques to assess plant sterility, survival and reproduction. : Research Associate – UNSW. Pairing new methods, like genomics, with classic techniques to assess plant sterility, survival and reproduction. Dr Patrick Finnerty: Postdoctoral Research Fellow – USYD. Conservation ecologist helping to bring wildlife back to improve ecosystems through rewilding and species reintroductions. HUMANITIES Dr Shauna Bostock: Indigenous Research Editor, Australian Dictionary of Biography – ANU. Multi-generational narrative history of the lived experience of Aboriginal people from colonisation to the present. Indigenous Research Editor, Australian Dictionary of Biography – ANU. Multi-generational narrative history of the lived experience of Aboriginal people from colonisation to the present. Dr Intifar Chowdhury: Lecturer in Government – Flinders University. A researcher passionate about better the political representation of all young Australians in our democracy. Lecturer in Government – Flinders University. A researcher passionate about better the political representation of all young Australians in our democracy. Dr Declan Humphreys: Lecturer, Cyber Security & Ethics – University of the Sunshine Coast. A philosopher exploring the ethics of emerging technologies such as AI. Lecturer, Cyber Security & Ethics – University of the Sunshine Coast. A philosopher exploring the ethics of emerging technologies such as AI. Dr Tatiana Bur: Lecturer & Cultural Historian – ANU. Focus is Ancient Greece with particular interests in Greek and Roman technology, especially mechanics. Lecturer & Cultural Historian – ANU. Focus is Ancient Greece with particular interests in Greek and Roman technology, especially mechanics. Dr Jac den Houling: Senior Research Fellow Olga Tennison Autism Research Centre - La Trobe University. Creating real-world change that benefits autistic people, in the areas that matter most to the autistic community. ARTS Lolita Emmanuel: Pianist/Doctor of Musical Arts candidate, Conservatorium of Music, USYD. Practice-based research with musicians in global Assyrian community, exploring how we use creative strategies to continue culture amid displacement. Pianist/Doctor of Musical Arts candidate, Conservatorium of Music, USYD. Practice-based research with musicians in global Assyrian community, exploring how we use creative strategies to continue culture amid displacement. Dr Sarah Rhodes: Sessional lecturer, School of Creative Arts - University of Tasmania. Uses photography and video to explore how the natural environment can guide an understanding of one's inner world. Sessional lecturer, School of Creative Arts - University of Tasmania. Uses photography and video to explore how the natural environment can guide an understanding of one's inner world. Shirin Barghnavard : Documentary Filmmaker & PhD Candidate - Edith Cowan University. Investigates the politics of representation in the documentary films of Iranian women, both within Iran and across the diaspora. : Documentary Filmmaker & PhD Candidate - Edith Cowan University. Investigates the politics of representation in the documentary films of Iranian women, both within Iran and across the diaspora. Sabrina Mackenzie: PhD candidate in Music Psychology - University of Melbourne. How music can be tool for cultivating self-compassion and improving emotional well-being. PhD candidate in Music Psychology - University of Melbourne. How music can be tool for cultivating self-compassion and improving emotional well-being. Jordan Alice Fyfe: PhD Candidate, School of Media, Creative Arts & Social Inquiry - Curtin University Working alongside disabled artists in WA to understand current barriers and co-create recommendations for transforming the disability arts sector. The ABC TOP 5 is presented with the crucial support our project partners: Creative Australia, University of Melbourne, University of Sydney and Australian National University. Leisa Bacon is the Executive Director Development & Strategic Partnerships at Creative Australia, which supports Australian Arts and Culture, and the ABC TOP 5 Arts. 'We're thrilled to partner with the ABC to empower research and creative practitioners to increase their impact through media training and skills development. This residency program enables the participants to better communicate their ideas to broad and diverse audiences, setting them up for the future.' Also essential for the ABC TOP 5 Arts is the support of the University of Melbourne. Professor Marie Sierra is the Dean of the Faculty of Fine Arts and Music. 'It's great to see this year's TOP 5 cohort – congratulations to all who have been selected from amongst the most diverse and talented artist-researchers in Australia. Time and again, the Residency has proven to be a focussing lens on the communication skills needed to advance the value and impact of creative arts research. We all look forward to seeing what new audiences, discoveries and innovations your time in the program will bring.' Professor Julie Cairney is the Interim Deputy Vice-Chancellor, Research at the University of Sydney, which proudly supports the ABC TOP 5 Humanities. 'In an era of rapid change and increasing complexity, it's essential that research and public dialogue go hand in hand. The ABC TOP 5 program empowers early career researchers to step into the media space with confidence, clarity, and purpose. By equipping them to share their insights with broad audiences, we're not only strengthening public understanding, but also ensuring that evidence-based perspectives remain central to national conversations.' The ANU supports the ABC TOP 5 Science, and Professor Kiaran Kirk, is the Dean of the ANU College of Science. 'This program is a fantastic way to celebrate some of our country's best early-career scientists, giving them a unique opportunity to hone their skills in explaining the importance of scientific research in addressing some of our biggest global challenges. Congratulations to this year's cohort.' For more information about the ABC TOP 5 head to: For media inquiries: Jonathan Webb: ABC TOP 5 Science Manager & Editor Science Simon Nicholas: Project Coordinator
News.com.au
2 hours ago
- News.com.au
Health Check: It's ‘nothing personal' as major US biotech fund calls time on Syntara
San Francisco's BVF Partners has exited all its ASX investments because they are too small for the fund's mandate Alcidion shares soar 15% on earnings upgrade Optiscan enters 'win-win' supplier collab Syntara (ASX:SNT) CEO Gary Phillips says the exit of a long-term US backer should not be seen as a judgment on the company's late-stage myelofibrosis drug program. In a block trade the San Francisco BVF Partners has disposed of its $5 million, 6%, Syntara stake. The shares were taken up by some of Syntara's existing institutional holders. BVF's exit last week sent Syntara shares down by 25%, despite the company's previous Friday's positive update on its phase II myelofibrosis trial update. Phillips says the trial news created a 'liquidity event' which BVF availed of. But it was not a case of BVF (as in Biotech Value Fund) spurning Syntara's drug program. Rather, the fund grew to the extent where it can't justify a minimum investment below US$30-50 million. 'They always liked our science,' Phillips says. 'They have visited our labs and were always encouraged, but they just got bigger and bigger.' With US$9 billion of assets, BVF has called time on all its ASX investments. In May BVF divested its $3 million in Actinogen Medical (ASX:ACW), also via a block trade. The fund had also invested in Opthea (ASX:OPT), but got off before the eye drug developer's' trials went pear shaped. BVF also invested in immune-oncology drug developer Viralytics, famously taken over by Merck for an eyebrow-raising $500 million in 2018. Syntara's blood cancer program looks the goods Syntara's 'liquidly event' stemmed from further data from its phase II myelofibrosis trial, evaluating its drug candidate SNT-5505 in combo with the standard-of-care drug ruxolitinib. The patients had been treated with ruxolitinib, so had symptoms such as enlarged spleen size and blood counts 'indicative of high disease burden'. The results showed eight of 11 evaluable patients (73%) achieved a reduction of more than 50% at 24 weeks, as measured by a standard gauge called TSS50. Four out of nine patients (44%) had a spleen volume reduction of 25% at week 24 or beyond. The ongoing trial enrolled 16 patients with intermediate or high-risk myelofibrosis, for 52 weeks of treatment. However, five dropped out by the 24-week mark. This is a 'withdrawal rate consistent with that seen in other myelofibrosis studies of patients with similar disease severity." Eight patients reaching 38 weeks showed and average 56% reduction in symptoms, while five reaching 52 weeks exhibited a 63% decline. Syntara intends to chat with the FDA in the September quarter about the design of a pivotal phase 2c/3 study. Too much of a good thing for Immutep? With four trial updates on separate programs in less than two months, immunology drug play Immutep (ASX:IMM) must also feel underappreciated. Immutep stock has fallen around 10% in this period and trades at close to five-year lows, despite the upbeat clinical vibes. Too much activity from the multi-tentacled Immutep confusing investors, perhaps? Today, Immutep said a phase I autoimmune study showed 'significant T-cell suppression', thus highlighting potential efficacy of its candidate IMP-761. Initial data from placebo-controlled, double-blinded effort also showed good safety at the highest dosing level to date. By stimulating the LAG-3 (lymphocyte-activation gene-3) agonist antibody, IMP-761 promises to treat conditions including rheumatoid arthritis, Type 1 diabetes and multiple sclerosis. Since May 5 Immutep also has updated investors on its head and neck cancer, lung cancer and soft tissue sarcoma trials. Miya My! Alcidion has upgraded earnings Hospital patient management software supplier Alcidion (ASX:ALC) has upped its full-year earnings outlook, with strong take-up of its flagship Miya prompting clients to adopt its broader wares. 'Over the past few months this has resulted in several customers of varying size seeking extensions or module upgrades," CEO Kate Quirke says. "This has contributed to our improved financial position." Having guided to earnings before interest, tax depreciation and amortisation of $3 million, the company now expects the number to exceed $4.5 million (for the year to June 30 2025). The company earlier guided to revenue of at least $40 million. Alcidion provides to more than 400 hospitals and 87 healthcare organisations in the UK, here and New Zealand. In the UK, the most capacious market, the beloved National Health Service (NHS) is being merged with Department of Health and Social Care. This poses both threat to – and opportunities for – Alcidion, given it sells to NHS organisations. In April, Quirke said the push for more NHS productivity with fewer staff was likely to mean greater demand for Alcidion's digital platforms. 'I see the opportunity increasing,' she said. 'But we are waiting to see what the ten-year plan indicates in terms of where the priority areas are.' PYC gets FDA OK PYC Therapeutics (ASX:PYC) has provided evidence that the FDA continues to function, with the agency approving the company's proposed trial design at a preliminary (Type B) meeting. The company currently is undergoing a phase 1-2 trial of its drug candidate VP-001, to treat the blinding eye disease retinitis pigmentosa type 11 (RP11). With positive data to date, PYC wants to progress to a phase2/3 study pitched at FDA approval. The FDA says PYC can use similar endpoints and says trial design features (such as use of a sham arm and inclusion exclusion criteria) are OK as well. The company will use this guidance to finalise its proposed registrational study design. Tryptamine study aims to put binge eating disorder to BED Meanwhile, Tryptamine Therapeutics (ASX:TYP) has won ethics approval for the world's first trial, to test intravenously infused psilocin for binge eating disorder (BED). BED is the most common eating disorder in the US and second most common here. BED results in multiple other conditions including depression, anxiety, PTSD (post-traumatic stress disorder) and compulsive behaviours. A collaboration with Swinburne University, the local trial will enrol 12 patients and administer them with with Tryptamine's drug candite TRP-8803. They will be given two doses 14 days apart and also undergo psychotherapy. The trial has started recruiting, with first dosing expected in the September quarter. Investors can expect top-line results before the year is out. The good OIL on a 'win-win' collab Optiscan (ASX:OIL) has entered a five-year collaboration agreement with the US based Long Grove Pharmaceuticals, which provides a contrast agent for Optiscan's fluorescence-based endomicroscopic imaging systems. The idea of the collab is to use Long Grove's fluorescein drug, AK-FLUOR, with Optiscan's imaging technology in clinical studies. This potentially will identify new applications for the drug and expedite regulatory submissions. On the Optiscan side of things, the data should support the company' efforts to win FDA approval for its Invue device. Invue enables surgeons to gain real-time pathology insights and make on-the-spot decisions. Optiscan CEO Dr Camile Farah dubs the agreement a 'clear-cut win-win for both companies' development strategies'.
